These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1234502)

  • 1. Blood level studies with viloxazine hydrochloride in man.
    Bayliss PF; Case DE
    Br J Clin Pharmacol; 1975 Jun; 2(3):209-14. PubMed ID: 1234502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of viloxazine hydrochloride in man.
    Vandel B; Vandel S; Jounet JM; Blum D
    Eur J Drug Metab Pharmacokinet; 1982; 7(1):65-8. PubMed ID: 7067726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between blood and cerebrospinal levels of the antidepressant agent viloxazine.
    Elwan O; Adam HK
    Eur J Clin Pharmacol; 1980; 17(3):179-82. PubMed ID: 7363931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of viloxazine hydrochloride.
    Vandel B; Vandel S; Allers G; Volmat R
    Pharmacopsychiatria; 1981 Mar; 14(2):66-70. PubMed ID: 7232498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetic study of conventional and sustained-release viloxazine in normal volunteers.
    Kergueris MF; Bourin M; Ribeyrol M; Beneroso N; Normand YL; Larousse C
    Neuropsychobiology; 1989; 20(3):136-40. PubMed ID: 2761683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment.
    Pisani F; Fazio A; Spina E; Artesi C; Pisani B; Russo M; Trio R; Perucca E
    Psychopharmacology (Berl); 1986; 90(3):295-8. PubMed ID: 3097715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A sensitive gas chromatographic assay for the determination of serum viloxazine concentration using a nitrogen-phosphorus-selective detector.
    Fazio A; Crisafulli P; Primerano G; D'Agostino AA; Oteri G; Pisani F
    Ther Drug Monit; 1984; 6(4):484-8. PubMed ID: 6515713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical pharmacology of viloxazine hydrochloride-a new anti-depressant of novel chemical structure.
    Bayliss PF; Duncan SM
    Br J Clin Pharmacol; 1974 Oct; 1(5):431-7. PubMed ID: 22454923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cases of overdosage with viloxazine hydrochloride (Vivalan).
    Brosnan RD; Busby AM; Holland RP
    J Int Med Res; 1976; 4(2):83-5. PubMed ID: 1026544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical and pharmacological study of the antidepressant activity of viloxazine in adult and elderly patients.
    Tosca P; Zerbi F; Romani A; Molini G; Cairoli S; Montagna M; Gabba A; Groppi A
    Int J Clin Pharmacol Ther Toxicol; 1985 May; 23(5):270-3. PubMed ID: 4008117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of administration route on pharmacokinetics of viloxazine in the rabbit.
    Thomare P; Bourin M; Kergueris MF; Ortega A; Larousse C
    Methods Find Exp Clin Pharmacol; 1992 Mar; 14(2):125-9. PubMed ID: 1598024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of viloxazine, its optical isomers and its major metabolites on biogenic amine uptake mechanisms in vitro and in vivo.
    Blackburn TP; Foster GA; Greenwood DT; Howe R
    Eur J Pharmacol; 1978 Dec; 52(3-4):367-74. PubMed ID: 729646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related differences in kinetics and side-effects of viloxazine in man and their clinical implications.
    Altamura AC; Melorio T; Invernizzi G; Colacurcio F; Gomeni R
    Psychopharmacology (Berl); 1983; 81(4):281-5. PubMed ID: 6419255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viloxazine (Vivalan ICI) in depression: results of a field trial of 276 patients in neuropsychiatric practice.
    Sebjanic V; Grombein S
    Adv Biochem Psychopharmacol; 1982; 32():113-20. PubMed ID: 7046360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viloxazine in depressed women: clinical response and cardiovascular effects.
    Corona GL; Frattini P; Cucchi ML; Santagostino G; Schinelli S; Zerbi F; Cairoli S; Tosca P; Savoldi F
    Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):322-7. PubMed ID: 3623737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viloxazine plasma concentrations and clinical response.
    Norman TR; Burrows GD; Davies BM; Maguire KP; Wurm JM
    J Affect Disord; 1980 Sep; 2(3):157-64. PubMed ID: 6210721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon.
    Meldrum BS; Anlezark GM; Adam HK; Greenwood DT
    Psychopharmacology (Berl); 1982; 76(3):212-7. PubMed ID: 6808538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age, therapeutic "milieu" and clinical outcome in depressive patients treated with viloxazine: a study with plasma levels.
    Altamura AC; Mauri MC; Guercetti G
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(1):67-75. PubMed ID: 3704174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of viloxazine in plasma by GLC.
    Norman TR; Burrows GD; Davies BM; Wurm JM
    Br J Clin Pharmacol; 1979 Aug; 8(2):169-71. PubMed ID: 486292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical profile and serum concentration of viloxazine as compared to amitriptyline.
    Müller-Oerlinghausen B; Rüther E
    Pharmakopsychiatr Neuropsychopharmakol; 1979 Jul; 12(4):321-37. PubMed ID: 386390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.